ArticleHuman vaccines & immunotherapeutics2026
Limited protective immunity to respiratory syncytial virus and pertussis among adults and healthcare workers in South Korea: A seroepidemiologic study.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) and pertussis remain important causes of community outbreaks and nosocomial transmission. However, age-stratified data on protective immunity in the general adult population and baseline immunity among healthcare workers (HCWs) in high-risk hospital departments are limited. We conducted a cross-sectional study among adults undergoing routine health checkups (n = 136) and a prospective cohort study of HCWs in the emergency department, pediatric, infectious disease, and pulmonology wards (n = 118). Antibodies indicative of protective immunity against RSV (pre-fusion IgG) and pertussis (anti-pertussis toxin IgG) were measured by ELISA using predefined thresholds. HCWs provided paired sera before and after the epidemic season (November and March) to assess seroconversion. Among health checkup examinees, RSV protective seroprevalence was 17.6% (16.9% intermediate, 0.7% high), highest in those aged ≥70 y (31.3%), while geometric mean titers (GMTs) were comparable across age groups. Pertussis protective seroprevalence was 13.2%, all within the intermediate range, without a significant age-related trend. Among HCWs, baseline RSV protective seroprevalence was 5.1%, with one seroconversion (0.8%) observed during follow-up. Pertussis protective seroprevalence among HCWs was 6.8%, with no confirmed infection-related seroconversion. GMTs for both pathogens were similar across departments. Protective immunity against RSV and pertussis was limited in both the general adult population and HCWs, indicating substantial susceptibility to seasonal and nosocomial transmission. These findings support strengthening adult pertussis booster strategies and highlight the need for further studies to evaluate targeted RSV vaccination approaches for HCWs in high-risk clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.